Skip to content

This site is intended for healthcare professionals in the UK only. Prescribing information and Adverse Event (AE) reporting details can be found in the footer.

  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs
  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs

How to administer: Dose titration

Gradual dose adjustments are important to optimise treatment for patients with type 2 diabetes

Two Zegluxen packs side-by-side

Gradual dose adjustments are important to optimise treatment for patients with type 2 diabetes

To facilitate gastro-intestinal tolerability of this therapy:1,2

Starting dose Week 2 onwards Week 3 onwards

Starting dose

0.6 mg liraglutide should be administered once daily.

Week 2 onwards

After at least 1 week on 0.6 mg once daily, the dose should be increased to 1.2 mg liraglutide.

Week 3 onwards

After at least 1 week on 1.2 mg once daily, depending on clinical response, some patients may benefit from an increase to 1.8mg, although daily doses above 1.8mg are not recommended.

Combinations and monitoring 

 

  • When liraglutide is added to a sulfonylurea or insulin, a dose reduction of the latter should be considered to reduce hypoglycaemia risk1
  • Combination therapy with sulfonylurea is only valid for adult patients1
  • Self-monitoring of blood glucose is not needed in order to adjust the dose of liraglutide,but is needed to adjust the dose of sulfonylurea and insulin, particularly when liraglutide therapy is started and
    insulin is reduced1
  • A stepwise approach to insulin dose reduction is recommended1
Man in wheelchair smiling at camera
  1. Zegluxen® (liraglutide) Summary of Product Characteristics.

000697557 | December 2024

Prescribing information can be found here

  • Navigation
    • Terms of Use
    • HCP Privacy
    • Cookies Policy
    • GDPR

MORE ABOUT US

linkedin

Reporting of side effects

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Zentiva Pharma UK Ltd via our online form (https://www.zentiva.co.uk/contact/mi-form), by email (UKMedInfo@zentiva.com) or by telephone (0800 090 2408).

Copyright Zentiva Group, a.s. © 2025

I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the gateway page after clicking on No.

No, I am not Yes, I am